• ITeos Therapeutics

  Participated · Series B · Apr 2020

  iTeos Therapeutics develops novel cancer immunotherapies and maintains a pipeline that includes drugs designed to influence the tumor microenvironment. The company is described as a biotech focused on new tumor immune therapies. Its development pipeline specifically includes agents that act on the tumor microenvironment. The article reports that iTeos recently received a strategic investment. The investors named are Boxer Capital and RA Capital Management. The amount of the investment was not disclosed in the article. iTeos Therapeutics is a clinical-stage biotechnology company developing next-generation immunotherapies that target the adenosine pathway and regulatory T cells (Tregs). Its lead programs are EOS-850, an adenosine A2A receptor antagonist in a Phase 1/2 study as a single agent and in combination, and EOS-448, a fully human ADCC‑enabled anti‑TIGIT antibody that entered the clinic. The company plans to initiate dosing for the combination cohorts of the EOS-850 trial in the second quarter of 2020 and recently initiated the Phase 1 portion of the EOS-448 Phase 1/2 study. Proceeds from the financing will support advancement of these clinical programs and additional first‑in‑class preclinical programs targeting the adenosine pathway and Tregs. iTeos is led by President and CEO Michel Detheux and is headquartered in Cambridge, MA with a research center in Gosselies, Belgium. iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on next-generation cancer immunotherapies targeting adenosine and regulatory T cell pathways. Its lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1b/2a study across four European sites with planned expansion to the United States. A second program, EOS-448, is a fully human ADCC-enabled anti-TIGIT antibody expected to enter Phase 1 in Belgium in early 2020. The company maintains headquarters in Cambridge, MA and a research center in Gosselies, Belgium. iTeos was founded by the Ludwig Institute for Cancer Research and the de Duve Institute. Financially, the company recently received non-dilutive support and has previously completed a $75 million (€64 million) Series B financing in 2018 led by MPM Capital. iTeos Therapeutics develops next-generation cancer immunotherapies with a pipeline focused on modulating the tumor microenvironment. The company plans to move EOS100850, an insurmountable and non‑brain penetrant adenosine A2A receptor antagonist, into the clinic in 2018 and toward clinical proof‑of‑concept, and EOS884448, an anti‑TIGIT antibody, into the clinic in 2019. Its pipeline also includes additional drug candidates targeting the tumor microenvironment. iTeos intends to use the proceeds from the financing to accelerate clinical development of its immuno‑oncology pipeline and to expand into new U.S. offices in Cambridge, Massachusetts. The company is led by CEO Michel Detheux, Ph.D., and was founded out of the Ludwig Institute for Cancer Research and the de Duve Institute in 2011. iTeos Therapeutics develops immuno-oncology drugs, focused on targeting the A2A adenosine receptor, immune checkpoints and non-immunogenic (“cold”) tumors. Its lead candidate is a proprietary A2A antagonist, and the company has a portfolio of additional immuno-oncology programs. iTeos has licensed its IDO1 program, which is in Phase 1 development, to Pfizer. The company uses a platform to identify rational combinations of immunotherapies and novel targets and emphasizes translational tumor immunology and early clinical-trial design. iTeos is based in Gosselies, Belgium and is a spin-off from Ludwig Cancer Research and the de Duve Institute (UCL). The company is supported in part by the Walloon Region and the FEDER. The recent funding will support clinical development activities and advance the launch of a clinical trial.

• Peloton Therapeutics

  Participated · Series E · Feb 2019

  Peloton Therapeutics is a clinical-stage drug discovery and development company focused on first-in-class oral medicines for cancer and other serious conditions. Its lead development program is PT2977, a potent and selective oral HIF-2α inhibitor targeting clear cell renal cell carcinoma and other disorders. The company emphasizes translating novel scientific insights into medicines for debilitating or life‑threatening conditions and notes that HIF-2α was previously thought to be intractable using small molecules. Proceeds from the recent financing will be used to advance Peloton’s research and development pipeline, including PT2977. RA Capital highlighted support as Peloton moves toward a Phase 3 trial of PT2977 for metastatic renal cell carcinoma and advances development in Von Hippel‑Lindau disease. The company issued the announcement from Dallas. Peloton Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule cancer therapies. Its lead programs are inhibitors of hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in kidney and other cancers. The company emphasizes first-in-class approaches that target unexploited molecular vulnerabilities. Peloton is advancing these programs through clinical development with the aim of impacting renal and other oncology indications. Financially, Peloton recently completed a Series D financing, increasing proceeds to support its programs. The company is publicly identified in the article as based in Dallas. Peloton Therapeutics is a clinical-stage biotech focused on discovering and developing first-in-class small-molecule cancer therapies. Its lead program, PT2385, is a first-in-class small molecule antagonist of hypoxia-inducible factor-2α (HIF-2α). PT2385 has generated reported responses in patients with renal cell carcinoma and is being considered for applications in von Hippel-Lindau disease, glioblastoma multiforme, and other high-unmet-need diseases. The company intends to advance its HIF-2α program and other research programs toward clinical goals. Peloton completed a $52.4 million Series D private financing to support these development plans. Management stated the financing positions the company to realize the full potential of its HIF-2α antagonists and continue its research efforts. Peloton Therapeutics is a Dallas-based early-stage cancer drug discovery and development company focused on small-molecule therapeutics. It is advancing a pipeline of several small molecule-based programs, each with distinct targets and mechanisms of action, in close collaboration with scientists at UT Southwestern. The company was founded by scientist Steven L. McKnight, Ph.D., and its board includes Nobel Laureate Michael S. Brown, John W. Creecy, David V. Goeddel, Tim Kutzkey and Brett A. Ringle. John A. Josey, Ph.D., former Vice President of Discovery Chemistry at Array BioPharma, will join Peloton as President and Chief Scientific Officer. Peloton completed an $18M Series A financing led by The Column Group, with participation from Remeditex Ventures and Peter O’Donnell, Jr. This Series A supplements an $11M grant recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).

• TCR2

  Led · Series B · Mar 2018

  TCR2 Therapeutics develops a novel class of T cell receptor (TCR)-based cellular therapies that harness the full signaling power of complete TCRs without HLA‑matching. Its proprietary multi-format TRuC™ platform reprograms the natural TCR complex to drive rapid cancer-cell killing with long persistence and low cytokine release. The company is advancing both solid tumor and blood cancer programs from this platform. Proceeds from the recent financing will advance two TRuC™-T cell programs through human proof-of-concept, including lead solid tumor candidate TC-210 targeting mesothelin. TCR2 also plans to expand its platform with dual-target TRuC™, immune cell enhancements and allogeneic technologies. The company is led by CEO Dr. Garry Menzel and is based in Cambridge, MA.

No current team members are available.